首页> 中文期刊>中国继续医学教育 >依达拉奉联合丁苯酞治疗脑梗死疗效观察

依达拉奉联合丁苯酞治疗脑梗死疗效观察

     

摘要

Objective To explore the clinical efficacy of edaravone and NBP treatment of patients with cerebral infarction.Methods From December 2014 to December 2015, 78 patients admitted in our hospital were randomly divided into two groups which were control group and observation group. The control group (38 patients) was treated with Salvia, aspirin and citicoline and conventional treatment, while the observation group (40 patients) adopted edaravone NBP treatment.Results After treatment, in the third day, seventh day, twenty-ifrst day and twenty-eighth day, the observation group's neurological deifcit scores were signiifcantly better than the control group (P<0.05). The observation group's effictive rate was 90.0% , signiifcantly better than the 71.1% of the control group (P<0.05).Conclusion Using edaravone and NBP in the treatment of cerebral infarction has a better clinical efficacy, improving neurological function deicitsscale, which should be promoted in clinical practice.%目的:探讨依达拉奉联合丁苯酞对脑梗死患者进行治疗的临床疗效。方法选取我院2014年12月~2015年12月收治的78例患者,并随机分为对照组和观察组,对照组(38例)采用丹参、阿司匹林以及胞二磷胆碱等药物进行常规治疗,观察组(40例)在此基础上采用依达拉奉联合丁苯酞进行治疗。结果在治疗后的第3 d、第7 d、第21 d、第28 d,观察组神经功能缺损评分优于对照组(P<0.05);观察组治疗有效率为90.0%,优于对照组的71.1%(P<0.05)。结论采用依达拉奉联合丁苯酞对脑梗死患者进行治疗,有较好的临床疗效,能够改善患者的神经功能缺损程度。

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号